Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
Company profile
Ticker
PRPO
Exchange
Website
CEO
Paul Kinnon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Revvity • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Seer • Prenetics Global Limited ...
Former names
TRANSGENOMIC INC
SEC CIK
Corporate docs
Subsidiaries
Precipio Diagnostics, LLC • Precipio SPV, Inc. ...
IRS number
911789357
PRPO stock data
Latest filings (excl ownership)
8-K
Precipio Announces Q1-2023 Shareholder Update Call
15 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
EFFECT
Notice of effectiveness
28 Apr 23
8-K
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
27 Apr 23
S-3/A
Shelf registration (amended)
25 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
CORRESP
Correspondence with SEC
25 Apr 23
UPLOAD
Letter from SEC
20 Apr 23
8-K
Entry into a Material Definitive Agreement
14 Apr 23
Transcripts
PRPO
Earnings call transcript
2023 Q1
17 May 23
PRPO
Earnings call transcript
2022 Q4
3 Apr 23
PRPO
Earnings call transcript
2022 Q3
14 Nov 22
PRPO
Earnings call transcript
2022 Q2
16 Aug 22
PRPO
Earnings call transcript
2021 Q4
4 Apr 22
PRPO
Earnings call transcript
2021 Q3
16 Nov 21
PRPO
Earnings call transcript
2021 Q2
27 Aug 21
PRPO
Earnings call transcript
2021 Q1
21 May 21
PRPO
Earnings call transcript
2020 Q4
1 Apr 21
PRPO
Earnings call transcript
2020 Q3
19 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm |
| Cash burn (monthly) | 434.67 k | 593.33 k | 1.01 mm | 918.17 k | 525.00 k | 580.17 k |
| Cash used (since last report) | 895.24 k | 1.22 mm | 2.08 mm | 1.89 mm | 1.08 mm | 1.19 mm |
| Cash remaining | 1.25 mm | 918.97 k | 60.81 k | 249.95 k | 1.06 mm | 946.09 k |
| Runway (months of cash) | 2.9 | 1.5 | 0.1 | 0.3 | 2.0 | 1.6 |
Institutional ownership, Q4 2022
9.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 19 |
| Opened positions | 4 |
| Closed positions | 3 |
| Increased positions | 7 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 1.08 bn |
| Total shares | 2.25 mm |
| Total puts | 0.00 |
| Total calls | 9.70 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 1.05 mm | $579.31 mm |
| BLK Blackrock | 579.47 k | $319.52 mm |
| Geode Capital Management | 256.61 k | $142.00 k |
| STT State Street | 114.91 k | $63.75 mm |
| Citadel Advisors | 55.92 k | $31.02 mm |
| Great Valley Advisor | 33.10 k | $18.25 mm |
| NTRS Northern Trust | 32.05 k | $17.67 mm |
| Stratos Wealth Partners | 30.00 k | $16.54 mm |
| Renaissance Technologies | 23.80 k | $13.00 k |
| Susquehanna International | 19.66 k | $10.91 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Jan 23 | Sandberg Richard A | Common Stock | Buy | Acquire P | No | No | 0.7765 | 20,000 | 15.53 k | 40,846 |
| 6 Jan 23 | Andrews Ronald Asbury | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Fisher Douglas | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Cossman Jeffrey | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Cohen David Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
News
Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression Of p190 & p210 Isoforms In A CML Patient By Using HemeScreen Technology
22 May 23
Precipio Signs Another HemeScreen Customer
4 May 23
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
28 Apr 23
Earnings Scheduled For April 3, 2023
3 Apr 23
Precipio Earnings Preview
31 Mar 23
Press releases
Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
22 May 23
Precipio Shares Growth Catalysts For HemeScreen
17 May 23
Precipio Announces Q1-2023 Shareholder Update Call
15 May 23
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
4 May 23
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
27 Apr 23